Background-A catheter-based approach after fibrinolysis is recommended if fibrinolysis is likely to be successful in patients with acute ST-elevation myocardial infarction. We designed a 2ϫ2 randomized, open-label, multicenter trial to evaluate the efficacy and safety of the paclitaxel-eluting stent and tirofiban administered after fibrinolysis but before catheterization to optimize the results of this reperfusion strategy. Methods and Results-We randomly assigned 436 patients with acute ST-elevation myocardial infarction to (1) bare-metal stent without tirofiban, (2) bare-metal stent with tirofiban, (3) paclitaxel-eluting stent without tirofiban, and (4) paclitaxel-eluting stent with tirofiban. All patients were initially treated with tenecteplase and enoxaparin. Tirofiban was started 120 minutes after tenecteplase in those patients randomly assigned to tirofiban. Cardiac catheterization was performed within the first 3 to 12 hours after inclusion, and stenting (randomized paclitaxel or bare stent) was applied to the culprit artery. The primary objectives were the rate of in-segment binary restenosis of paclitaxel-eluting stent compared with that of bare-metal stent and the effect of tirofiban on epicardial and myocardial flow before and after mechanical revascularization. At 12 months, in-segment binary restenosis was similar between paclitaxel-eluting stent and bare-metal stent (10.1% versus 11.3%; relative risk, 1.06; 95% confidence interval, 0.74 to 1.52; Pϭ0.89). However, late lumen loss (0.04Ϯ0.055 mm versus 0.27Ϯ0.057 mm, Pϭ0.003) was reduced in the paclitaxel-eluting stent group. No evidence was found of any association between the use of tirofiban and any improvement in the epicardial and myocardial perfusion. Major bleeding was observed in 6.1% of patients receiving tirofiban and in 2.7% of patients not receiving it (relative risk, 2.22; 95% confidence interval, 0.86 to 5.73; Pϭ0.14). Conclusions-This trial does not provide evidence to support the use of tirofiban after fibrinolysis to improve epicardial and myocardial perfusion. Compared with bare-metal stent, paclitaxel-eluting stent significantly reduced late loss but appeared not to reduce in-segment binary restenosis. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique identifier: NCT00306228. (Circ Cardiovasc Interv. 2010;3:297-307.) Key Words: acute myocardial infarction Ⅲ fibrinolysis Ⅲ postfibrinolysis angioplasty Ⅲ tirofiban Ⅲ IIb/IIIa inhibitors Ⅲ paclitaxel Ⅲ drug-eluting stents T he preferred reperfusion therapy in patients with acute ST-elevation myocardial infarction (STEMI) is primary percutaneous coronary intervention (PCI). 1 However, many hospitals, even in the United States and Europe, lack PCI facilities, and few provide around-the-clock staffing for these procedures. 2 Thus, fibrinolysis is administered to eligible patients if primary PCI cannot be performed in a timely fashion. Recent studies have demonstrated that routine ad-
junctive or early postfibrinolytic angiography and, if appropriate, PCI may improve outcome. [3] [4] [5] [6] [7] [8] [9] [10] [11] This approach combines the advantages of the rapid and simple use of fibrinolysis for myocardial salvage with those of stenting in achieving a normal stable flow and is a reasonably useful strategy in most patients even in the absence of ischemia at rest or after stress, arrhythmias, left ventricular dysfunction, or heart failure. 12, 13 However, the most effective dose and timing of antiplatelet therapy remains unresolved, as does the safety and efficacy of drug elution.
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We performed an open-label, 2ϫ2, controlled, randomized trial in STEMI patients receiving fibrinolysis, enoxaparin, and aspirin followed by early cardiac catheterization and coronary stenting to compare the efficacy of the paclitaxeleluting stent with that of the conventional bare-metal stent in restenosis. We also determined the effect of tirofiban administered 120 minutes after fibrinolysis but before PCI on epicardial and myocardial flow both before and after mechanical revascularization.
Methods

Patient Population
From October 2004 to August 2006, patients were enrolled from 20 Spanish hospitals, 13 of which had interventional facilities. The inclusion criteria were as follows: age 18 years or older; symptom onset within 12 hours before random assignment; chest pain lasting more than 30 minutes; ST-segment elevation of at least 0.1 mV in at least 2 limb leads, ST-segment elevation of at least 0.2 mV in 2 or more contiguous precordial leads, or left bundle-branch block or paced rhythm; and no severe heart failure (Killip class Ͻ3). The exclusion criteria were as follows: cardiogenic shock, defined as a systolic blood pressure Ͻ90 mm Hg with no response to fluid administration or Ͻ100 mm Hg in patients with supportive treatment and no bradycardia; suspected mechanical complications of acute myocardial infarction; previous coronary artery bypass graft; noncardiac disease that is likely to jeopardize the planned termination of the study; women of childbearing potential unless they had a negative pregnancy test result; active bleeding and recent surgery (within 2 weeks) that contraindicate the use of heparin, tirofiban, or platelet aggregation inhibitors; contraindications for thrombolysis (previous hemorrhagic stroke at any time, history of nonhemorrhagic cerebrovascular accident within the previous 12 months, intracerebral neoplasm, active internal bleeding, suspected aortic dissection, uncontrolled hypertension Ͼ180/110 in several measurements, any other known intracerebral condition not covered in contraindications, current use of anticoagulants or heparin use within 8 hours, known bleeding diathesis, recent trauma [Ͻ4 weeks] including head trauma or traumatic or prolonged [Ͼ10 minutes] cardiopulmonary resuscitation or recent major surgery or biopsy [Ͻ8 weeks], noncompressible vascular punctures, recent [Ͻ4 weeks] internal bleeding, pregnancy, and active peptic ulcer); history of hypersensitivity to aspirin, ticlopidine, clopidogrel, heparin, tirofiban, or stainless steel; known renal failure, creatinine Ͼ2.5 mg/dL; known impaired hepatic function that contraindicates the use of clopidogrel; known thrombocytopenia (Ͻ100 000); participation in other trials; known multivessel disease identified as not suitable for revascularization; and known peripheral vascular disease that makes cardiac catheterization difficult.
Approval was obtained from the relevant ethics committees at both national and institutional level. An informational brochure was provided to each patient who met the inclusion criteria, and informed written consent was obtained. All patients were then randomly assigned using a central telephone system, and the doctors who informed the patient rang for the allocation. Blocking was used to generate the random allocation sequence and to ensure a close balance of the numbers in each group at any time during the trial. The block lengths were 4, 8, and successive 4 size blocks. Patients admitted to noninterventional hospitals were transported to the nearest interventional hospital and returned to the original hospital after angiography and revascularization.
Study Protocol and Interventions
After providing informed consent, patients who satisfied the inclusion and exclusion criteria were randomly assigned to 1 of 4 treatment groups: (1) bare-metal stent without tirofiban, (2) baremetal stent with tirofiban, (3) paclitaxel-eluting stent without tirofiban, and (4) paclitaxel-eluting stent with tirofiban. All patients received fibrinolysis and aspirin, and the use of tirofiban or paclitaxel-eluting stent was evaluated on this background therapy.
Patients randomly assigned to tirofiban received 150 mg to 325 mg of nonenteric coated aspirin orally (chewed) or 500 mg iv as soon as STEMI was identified. Immediate thrombolysis with tenecteplase was administered according to the instructions in the Summary of Product Characteristics for the treatment of STEMI (30 mg if body weight was less than 60 kg, 35 mg if it was 60 to 69 kg, 40 mg if it was 70 to 79 kg, 45 mg if it was 80 to 89 kg, and 50 mg if it was 90 kg or more). No enoxaparin bolus was given to these patients; enoxaparin was administered as a subcutaneous injection at 0.75 mg/kg. This subcutaneous dose was the only dose administered if the coronary intervention was successfully performed within 8 hours of randomization. Tirofiban was started 2 hours after tenecteplase with a fixed 25-g/kg intravenous bolus followed by 0.15 g/kg/min in intravenous infusion for 24 hours. The infusion was reduced by 50% if severe renal failure (creatinine clearance Յ30 mL/h or creatinine Ͼ2 mg/dL) was observed. The rationale for withholding tirofiban for 2 hours after fibrinolytic treatment was based on the pharmacokinetics and pharmacodynamics of tenecteplase. In a previous study with 103 patients, 14 tenecteplase exhibited biphasic elimination from the plasma with a mean initial half-life of 22 minutes and a mean terminal half-life of 115 minutes. This mean terminal half-life of 115 minutes motivated the rationale for withholding tirofiban for 2 hours in order to avoid bleeding complications.
Patients randomly assigned to no tirofiban received 150 mg to 325 mg of non-enteric-coated aspirin orally (chewed) or 500 mg iv as soon as STEMI was identified. Immediate thrombolysis with tenecteplase was administered, with the doses and mode of administration described above. An enoxaparin bolus of 30 mg followed by a subcutaneous dose of 1 mg/kg was administered in patients Յ75 years old. Patients over 75 did not receive the enoxaparin bolus and the subcutaneous injection was reduced to 0.75 mg/kg. This subcutaneous dose was also the only dose administered if coronary intervention was successfully performed within 8 hours of random assignment.
Patients underwent catheterization within 3 to 12 hours of random assignment. The infarct-related artery was dilated if there was total occlusion, the stenosis was greater than 50%, or the TIMI flow grade was less than 3. Stenting of culprit lesions was performed when they were morphologically suitable for stenting and when the procedure was expected to achieve an adequate result. To avoid thrombus compression and embolization, direct stenting was attempted when possible. The stenting procedure was carried out using Express stents (Boston Scientific, Natick, Mass) or TAXUS stents (Boston Scientific), for patients randomly assigned to the bare-metal stent or paclitaxel-eluting stent, respectively. When a large amount of myocardium was threatened by severe stenosis (Ͼ90% reduction in lumen diameter by visual estimation in a coronary segment with a reference diameter larger than 2.75 mm), stenting of nonculprit lesions was also performed.
No additional low-molecular-weight heparin was administered if revascularization was successful. In the group randomly assigned to no tirofiban, investigators were encouraged not to use glycoprotein IIb/IIIa inhibitors during the revascularization procedure. If the investigator decided that a glycoprotein IIb/IIIa inhibitor was required during the procedure, tirofiban was suggested as a bail-out.
Immediate rescue angioplasty was undertaken when both chest pain and ST-segment elevation persisted at 3 hours after administration of tenecteplase.
Immediately after stenting, patients received a loading dose of 300 mg of clopidogrel and 75 mg daily for 1 year. Maintenance aspirin therapy was administered indefinitely at 80 to 325 mg once daily (coated or uncoated), unless contraindicated. The tirofiban infusion was stopped 24 hours after initiation. Finally, ␤-blockers, angiotensin-converting enzyme inhibitors, statins, and any additional postinfarction therapy were administered, as outlined in international guidelines. 13, 15 
Study End Points and Definitions
The primary objectives of the study were, first, to compare the efficacy of the paclitaxel-eluting stent with that of the conventional bare-metal stent, and, second, to determine the effect of tirofiban administered 120 minutes after fibrinolysis but before PCI on epicardial and myocardial reperfusion in patients with STEMI treated with routine early postfibrinolysis PCI.
For the first objective, the primary efficacy end point was the rate of binary restenosis after 12 months of angiographic follow-up, as determined by independent quantitative angiographic analysis. Binary angiographic restenosis was defined as a Ͼ50% narrowing of the lumen diameter in the target segment (defined as all portions of the vessel that received treatment within the stent zone, including the proximal and distal 5-mm margins).
For the second objective, the primary efficacy end point was the degree of epicardial and myocardial flow before and after mechanical revascularization. This was measured angiographically using the angiographic perfusion score (APS). The APS combines grades of epicardial and myocardial perfusion before and after PCI to arrive at a single angiographic variable that is associated with infarct size and clinical outcomes. 16 The APS is calculated by summing the epicardial and myocardial flow grades before and after PCI (total possible grade, 0 to 12). Full perfusion is defined as an APS of 10 to 12, partial perfusion as an APS of 4 to 9, and failed perfusion as an APS of 0 to 3.
Prespecified secondary endpoints included the safety of the paclitaxel-eluting stent in terms of rate of stent thrombosis, determination of the interaction between the paclitaxel-eluting stent and the complicated myocardial infarction lesion in terms of reduction in intimal proliferation as evaluated by quantitative coronary angiography, and determination of the clinical efficacy and safety of full-dose fibrinolysis plus delayed tirofiban compared with fibrinolysis alone, both in the whole cohort of patients and in different subgroups. The clinical definitions provided were identical to those used in the previous GRACIA 1 and 2 trials 4,10 ; as for example major bleeding was defined as any bleeding complication causing death, need for surgery or transfusion, or extended time in hospital. We followed the Academic Research Consortium (ARC) criteria for classifying stent-related thrombosis events in an attempt to establish uniformity. 17
Data Collection and Core Laboratory Analysis
Data were entered using a double entry system, and the accuracy of collected data were validated against medical records by an independent clinical research organization (Chiltern International, Spain S.A.). Data were then submitted to the data coordinating center (Hospital General Universitario Gregorio Marañón, Madrid). Clinical outcome was adjudicated by an independent clinical events committee blinded to study group assignment. A separate data and safety monitoring board not affiliated with the study investigators reviewed data periodically throughout the trial to identify potential safety issues and monitor study conduct.
Coronary angiography was performed at baseline, at the completion of the procedure, and after 12 months of follow-up. All angiograms were analyzed at an independent angiographic core laboratory (ICICOR, Valladolid, Spain) with a quantitative computer-based system (Medis, Leesburg, Va). The epicardial and myocardial flow grades were assessed by an experienced reader who was blinded to treatment assignment and clinical outcome.
Additional assessment of myocardial perfusion was performed using ST-segment analysis. The amount of ST-segment elevation was measured manually 20 ms after the J point. The sum of ST-segment elevation was measured from leads I, aVL, and V 1 to V 6 for anterior myocardial infarction and leads II, III, aVF, V 5 , and V 6 for inferior myocardial infarction. We divided patients into 3 groups according to the resolution of ST-segment deviation (complete, Ն70% resolution; partial, Ͼ30% but Ͻ70% resolution; and no resolution, Յ30% resolution).
Statistical Analysis
The number of patients included in the study was based on an estimate of the sample size needed to identify a statistically significant difference in the 2 principal endpoints. Thus, for the sample size calculation, we used 2 different variables: binary restenosis (categorical variable) and the APS (categorical variable).
For binary restenosis, we assumed that the restenosis rate in the bare-metal stent group would be 22% and that this rate would be clinically significant if it was reduced by 50% (from 22% to 11%) in the paclitaxel-eluting stent group. The predicted restenosis rate with the bare-metal stent and the assumed benefit with the paclitaxeleluting stent were determined using data from the CADILLAC 18 and the TAXUS IV 19 studies. Based on the assumed restenosis rate, to have at least 80% power at the overall 5% significance level (2-tailed), the trial had to enroll a total of 436 patients. We expected a 20% loss to follow-up (a 12-month angiographic follow-up is required for this assumption).
For the APS, the sample size calculation was based on the assumption that full APS is present in approximately 50% of patients with STEMI who had received fibrinolytics 16 and that this rate would be clinically significant if it increased by 25% (from 50% to 62.5%) in the tirofiban group. On the basis of this assumption, with 80% power at the overall 5% significance level (2-tailed), the trial should enroll a total of 408 patients to show the superiority of treatment with tirofiban. We expected a 5% loss to follow-up (pre-and post-PCI angiography is required for this assumption).
All the analyses were performed according to the intention-to-treat principle. We analyzed the primary and secondary efficacy and safety end points using the 2 test or Student t test. Additionally, we used the 2 test for trend to analyze categorical variables or the ANOVA test to analyze quantitative variables, in each of the 4 groups. The data are presented as the mean and the standard error, medians and interquartile range, or proportions. A 2-tailed probability value of Ͻ0.05 indicated statistical significance. Figure 1 shows the trial profile: 110 patients were initially randomly assigned to receive no tirofiban and a bare-metal stent, 107 to receive tirofiban and a bare-metal stent, 110 to receive no tirofiban and a placlitaxel-eluting stent, and 109 to receive tirofiban and a paclitaxel-eluting stent. Three patients (1 in each of the last 3 groups) were excluded from the analysis because they did not meet the inclusion criteria. Of the 433 patients, 147 (34%) were included and randomly assigned to hospitals with no PCI facilities; they were subsequently transferred to a hospital with PCI facilities, where the remaining 286 of 433 (66%) patients were also included and randomly assigned. Eleven (7.5%) patients had cardiac complications during the transfer: 8 of 147 (5.4%) had cardiac arrhythmias, 1 of 147 (0.7%) had heart failure, and 2 of 147 (1.4%) had ischemic pain. These were all successfully resolved during transport. Overall, the baseline characteristics of the study population were similar between groups and similar to those of the populations of previous trials on primary angioplasty or fibrinolysis ( Table 1 ). All groups had a similar time delay between the onset of symptoms and randomization and between randomization and angiography. Fibrinolysis was administered immediately after randomization. Thus, randomization and fibrinolysis times are equivalent. The median transportation distance to the nearest PCI center was 45 km (range, 10 to 120 km) and the median transportation time was 61 minutes (range, 10 to 137 minutes). There were no differences in concomitant medication given during hospitalization, at discharge (Table  1) , or after the 12-month follow-up in either group. After 12 months of follow-up, high proportions of patients were on ␤-blockers (85%), angiotensin-converting-enzyme inhibitors or angiotensin II receptor antagonists (58%), statins (81%), aspirin (96%), and thienopyridines (89%).
Results
Patient Characteristics
Postfibrinolysis angiography was performed in 419 of 433 (97%) patients (Figure 1 ). Eight patients died before angiography could be undertaken. One patient did not undergo angiography because of a clear false-positive diagnosis on arrival at the hospital, 1 because no vascular access was obtained, 1 because of cerebral hemorrhage, 1 refused angiography and withdrew from the study after fibrinolysis was administered, and 2 because of their physician's decision. Table 1 also shows baseline angiographic characteristics.
Angioplasty of the culprit lesion was attempted in 364 (87%) of 419 patients who underwent postfibrinolysis an-giography; stents were implanted in all of these patients, of whom 57% underwent direct stenting. Stenting of nonculprit lesions was performed in 128 of 419 (31%) of the patients who underwent catheterization. No differences were found between the groups. Of the 55 patients who underwent angiography but did not undergo angioplasty, 21 had no significant angiographic stenosis. Among the remaining 34 patients, 27 were recommended for medical treatment because of coronary artery disease that was unsuitable for PCI or revascularization by coronary bypass surgery and seven patients underwent predischarge coronary artery bypass surgery due to multivessel coronary disease that made stenting unsuitable. We found no differences among the 4 groups in the number of patients with no significant angiographic stenosis or in those treated medically or with bypass surgery.
Tirofiban was administered to 204 (95%) of 214 patients in the tirofiban group. Bailout tirofiban was administered in 2 (1%) of 215 patients in the no tirofiban group who underwent angiography. Angiography did not reveal differences favoring postfibrinolysis tirofiban administration in TIMI grade 3 flow, TIMI grade 3 myocardial perfusion scores, or corrected TIMI frame counts, either in the initial angiography or after the procedure ( Table 2 ). The rates of APS (the primary end points for evaluation of epicardial and myocardial perfusion) were similar in patients with and without tirofiban ( Figure 2 ). Data are presented as n (%) or meanϮstandard error. *Medical treatment at inclusion represents medical treatment received by the patient before random assignment. The use of aspirin was high because patients received it at the onset of STEMI by the Emergency Services, primary care doctors, or emergency at referral hospitals.
Furthermore, ST-segment resolution was also similar in patients with or without tirofiban ( Figure 3) .
Angiographic follow-up at 12 months was completed in 299 of 346 (86%) eligible patients ( Figure 1 ) at a median of 382 days, and data were analyzed at the core angiographic laboratory ( Table 3 ). The rate of the major primary end point, analysis-segment binary restenosis (which includes measurements within the stent and 5 mm proximal and distal to the stent), was similar for both the bare-metal and paclitaxeleluting stent: 11.3% (16/142) for the bare-metal stent and 10.1% (15/149) for the paclitaxel-eluting stent (relative risk, [RR], 1.06; 95% confidence interval [CI], 0.74 to 1.52; Pϭ0.89). In-segment late lumen loss was significantly lower for the paclitaxel-eluting stent than for the bare-metal stent (0.04Ϯ0.055 mm versus 0.27Ϯ0.057 mm, difference, Ϫ0.23 [95% CI, Ϫ0.39 to Ϫ0.07] Pϭ0.003).
The 12-month clinical follow-up was complete for almost all patients (Figure 1) . Table 4 shows the clinical outcomes and safety parameters. The combined rates of death, recurrent myocardial infarction, revascularization, and/or rehospitalization were similar for all 4 groups: 21.0% in patients randomly assigned to tirofiban compared with 15.5% in patients ran-domly assigned to no tirofiban (relative risk with tirofiban, 1.19; 95% CI, 0.96 to 1.49; Pϭ0.174) and 21.2% in patients randomly assigned to the paclitaxel-eluting stent as compared with in 15.3% patients randomly assigned to bare-metal stents (RR with paclitaxel-eluting stent; 1.20; 95% CI, 0.97 to 1.49; Pϭ0.141). The individual rates of death, reinfarction, revascularization, rehospitalization, and stent thrombosis were also similar in all 4 groups in the comparison between tirofiban and no tirofiban and in the comparison between the paclitaxel-eluting stent and the bare-metal stent after 12 months of follow-up (Table 4 ). Finally, we also performed a per protocol analysis (data not shown) for the primary and safety end points in patients who strictly followed the protocol (protocol violations excluded). The results were similar to those presented above.
Discussion
This study shows that in STEMI patients treated with PCI after fibrinolysis, routine initiation of a glycoprotein IIb/IIIa inhibitor 2 hours after fibrinolysis in combination with aspirin, enoxaparin, and clopidogrel does not improve epicardial or myocardial perfusion before or after PCI. Furthermore, the use of a paclitaxel-eluting coronary stent in these patients did not significantly reduce binary restenosis overall in the 12 months after the intervention; however, it did reduce late loss and minimal luminal diameter.
The use of a platelet glycoprotein IIb/IIIa inhibitor has been evaluated elsewhere as adjunctive therapy in STEMI patients undergoing coronary reperfusion with either primary PCI or fibrinolysis. Among patients undergoing primary PCI, periprocedural administration of glycoprotein IIb/IIIa inhibitors improves outcome in patients with STEMI, compared with placebo. 20, 21 However, a separate issue is the optimal timing of glycoprotein IIb/IIIa inhibitor therapy. Although administration of a glycoprotein IIb/IIIa inhibitor in the ambulance or emergency department rather than in the catheterization laboratory is associated with a significant increase in pre-PCI angiographic perfusion, no difference in post-PCI angiographic perfusion, or in clinical outcomes has been observed. 22 Further studies, as the FINESSE trial, 23 failed even to document a significant increase in pre-PCI TIMI flow grade of 3 when comparing patients receiving abciximab alone before PCI or undergoing primary PCI (14.1% versus 12.0%, Pϭ0.219). In patients undergoing fibrinolysis, the antiplatelet potency of glycoprotein IIb/IIIa inhibitors made these drugs particularly useful when attempting to restore coronary perfusion and reduce the incidence of recurrent ischemia. 24, 25 Despite these hypothetical benefits, 2 large clinical trials, testing the combination of half-dose of lytics and IIb/IIIa inhibitors, the GUSTO V and ASSENT-3, together with the meta-analysis by Keeley, showed that simultaneous combination therapy does not improve survival compared with conventional fibrinolytic therapy, and that it increases bleeding complications. 22, 26, 27 To our knowledge, ours is the first study to evaluate the benefit of glycoprotein IIb/IIIa inhibitors administered 120 minutes after fibrinolysis but before early routine PCI to accelerate fibrinolytic recanalization and to improve angiographic perfusion in patients with STEMI. Full doses of fibrinolysis followed by delayed full doses of glycoprotein IIb/IIIa inhibitors did not improve pre-PCI or post-PCI angiographic perfusion, and, as previously shown with the simultaneous combination of both drugs (usually half doses of fibrinolysis and glycoprotein IIb/IIIa inhibitors), these agents also increase the rate of major bleeding. Thus, our results argue against routine treatment with glycoprotein IIb/IIIa inhibitors in this scenario and with this timing. We postulate several explanations for the lack of significant treatment benefit with delayed postfibrinolysis use of tirofiban in our study. First, patients were treated with aggressive contemporary reperfusion therapies, including full doses of tenecteplase and enoxaparin, which may have reduced the potential incremental effect of tirofi- 
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The GRACIA-3 Trial ban. Furthermore, such a benefit may have been attenuated by the shorter time between initiation of symptoms and fibrinolysis (median, 2.92 hours) or between fibrinolysis and PCI (median, 5.16 hours). Thus, considering that tirofiban was administered at least 2 hours after fibrinolysis, the time gain for tirofiban was short in most patients. A separate issue is the optimal timing between fibrinolysis and PCI, as trials show some overlap in the timing of PCI 3-11,22,23,28 -31 and this leads to different, somewhat arbitrary definitions. Facilitated PCI involves pharmacological therapy before planned primary PCI for STEMI to achieve an open infarctrelated artery before arrival at the catheterization laboratory. Trials have been conducted using fibrinolytic agents, glycoprotein IIb/IIIa inhibitors, and combinations of both. In contrast, adjunctive or early elective PCI is used in patients who are initially successfully reperfused with fibrinolysis and in whom early catheterization and, if appropriate, PCI is performed. Our trial would be better placed in the second definition, although the distinction between facilitated and adjunctive/early angioplasty is somewhat arbitrary.
There are few data on the use of drug-eluting stents in STEMI. [32] [33] [34] [35] [36] [37] [38] [39] Information is restricted to drug-eluting stents used during primary PCI, when they appear to be associated with a marked and sustained reduction in the rate of restenosis and the attendant risks of repeat revascularization after PCI. Concerns exist, however, over the safety of these stents, particularly in terms of the risk of stent thrombosis. To the best of our knowledge, no randomized trial has specifically examined the efficacy and safety of drug-eluting stents in the setting of postfibrinolysis adjunctive routine PCI for STEMI. Our results demonstrate that implantation of a paclitaxeleluting stent during adjunctive routine postfibrinolysis PCI was safe but did not result in overall decreased angiographic in-segment binary restenosis. On the other hand, the use of a paclitaxel-eluting stent did lead to a decrease in the extent of late lumen loss, as compared with the use of a bare-metal stent, thus suggesting a reduced risk of restenosis. We postulate several explanations for the lack of significantly reduced binary restenosis (primary end point) with the use of the paclitaxel-eluting stent in our study. First, we underesti- mated the power of the effect of bare-metal stent implantation on the rate of follow-up binary restenosis (11% and not 22%). 18, 36, 37, 39 Our strategy of postfibrinolysis PCI represents a different approach to mural thrombus in damaged plaque from that of primary PCI, and, consequently, reduced neointimal proliferation must be confirmed in future studies. Second, studies carried out since the initiation of our trial have shown that late loss is more reliable than restenosis rates at determining neointimal proliferation between drug-eluting and bare-metal stents, particularly in early efficacy studies. 40, 41 The mean late lumen loss was significantly lower (0.04Ϯ0.055 versus 0.27Ϯ0.057 mm, Pϭ0.003) in the paclitaxel-eluting group than in the bare-metal group in our study, as we failed to define binary restenosis, instead of late lumen loss, as our primary end point. Some important limitations must be admitted regarding the interpretation of our results. First, we use surrogate endpoints to compare four strategies of postfibrinolysis PCI rather than rely on clinical outcomes. However, the mechanistic end points chosen are validated, and core laboratory-blinded interpretation of the data were performed. Second, it is not unthinkable that earlier administration of tirofiban might have led to different results, although the bleeding rates might be increased by the concomitant administration of fibrinolytic treatment and tirofiban. Third, and very importantly, this trial did not properly address the issue of rescue angioplasty for failed fibrinolysis, as it was designed before recent findings documenting the importance of early resolution of STsegment elevation as an independent guide for the indication rescue angioplasty. 42 Fourth, the use of an angiographic end point to assess restenosis implied that repeat angiography could strongly affect the repeat revascularization rates, which tend to be largely increased compared with those that occur in the setting of clinically driven repeat angiography. In our experience, 11 of 299 (3.7%) patients with 12-months angiographic follow-up underwent repeat revascularization under this condition. Finally, as stated, the study was undersized (bare metal stent restenosis was 11%, not 22%), and clopidogrel was not given on admission, as is now recommended by the guidelines.
Despite these limitations, our results have important implications for the use of tirofiban and paclitaxel-eluting stents in patients with STEMI undergoing early routine postfibrinolysis angioplasty. First, the routine use of tirofiban at least 120 minutes after fibrinolysis but before PCI was not superior to fibrinolysis alone for improvement of epicardial and myocardial perfusion. Furthermore, patients in the tirofiban group had a 1.1-to 1.7-fold increased risk of major and minor bleeding that significantly impacted 1-year all-cause mortality in our experience. Second, compared with bare-metal stents, paclitaxel-eluting stents significantly reduced late loss but appeared not to reduce in-segment binary restenosis.
